Certara Inc
NASDAQ:CERT

Watchlist Manager
Certara Inc Logo
Certara Inc
NASDAQ:CERT
Watchlist
Price: 10.58 USD -1.21% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Certara Inc?
Write Note

Gross Margin
Certara Inc

59.7%
Current
60%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.7%
=
Gross Profit
222.5m
/
Revenue
372.8m

Gross Margin Across Competitors

Country US
Market Cap 1.7B USD
Gross Margin
60%
Country US
Market Cap 36.3B USD
Gross Margin
74%
Country US
Market Cap 31.3B USD
Gross Margin
83%
Country AU
Market Cap 26.7B AUD
Gross Margin
100%
Country US
Market Cap 10.7B USD
Gross Margin
90%
Country US
Market Cap 6.3B USD
Gross Margin
67%
Country JP
Market Cap 934B JPY
Gross Margin
58%
Country US
Market Cap 5.5B USD
Gross Margin
85%
Country SE
Market Cap 53.5B SEK
Gross Margin
47%
Country US
Market Cap 2.4B EUR
Gross Margin
66%
Country CN
Market Cap 16.2B CNY
Gross Margin
43%
No Stocks Found

Certara Inc
Glance View

Market Cap
1.7B USD
Industry
Health Care

Certara Inc., founded in 2008, has emerged as a pivotal player in the realm of virtual drug development, leveraging its sophisticated model-based drug development technology to transform how pharmaceutical companies strategize and optimize drug discovery. The company's core strength lies in its comprehensive suite of biosimulation software and services, which predict how drugs behave in the human body. This revolutionary approach allows pharmaceutical companies to refine their drug development processes, increase efficiency, and reduce the time and cost associated with bringing new drugs to market. By providing insights into drug interactions, efficacy, and safety, Certara aids its clients in making informed decisions early in the development cycle, essentially becoming an indispensable ally in navigating the complex and costly landscape of drug development. Certara generates revenue primarily through software licensing and consulting services, establishing long-term partnerships with its diverse clientele, which includes over 1,850 companies worldwide, including prominent pharmaceutical giants and regulatory agencies. By embedding itself into the critical processes of drug development, Certara garners not just the upfront licensing fees but also ongoing consulting fees that allow pharmaceutical companies to fine-tune and optimize their drug development strategies continuously. As healthcare industries place increasing emphasis on precision medicine and personalized healthcare, Certara's role as a guide in these innovations becomes even more pronounced, ensuring its financial health and relevance in a highly competitive field. The company's growth reflects a keen understanding of its niche, capitalizing on its unique offerings to remain at the forefront of scientific innovation.

CERT Intrinsic Value
11.44 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.7%
=
Gross Profit
222.5m
/
Revenue
372.8m
What is the Gross Margin of Certara Inc?

Based on Certara Inc's most recent financial statements, the company has Gross Margin of 59.7%.